Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.026808559735579367 | N/A |
Market Cap | $6.30M | N/A |
Shares Outstanding | 234.84M | 54.17% |
Employees | 0 | N/A |
Shareholder Equity | 9.50M | -46.89% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.70 | N/A |
P/S Ratio | 0.60 | N/A |
P/B Ratio | 0.66 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.9445 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $10.54M | N/A |
Earnings | -$8.97M | N/A |
EPS | -0.0382 | N/A |
Earnings Yield | -1.42 | N/A |
Gross Margin | 0.5669 | N/A |
Operating Margin | -0.9043 | N/A |
Net income margin | -0.8515 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $25.42M | N/A |
Total Debt | $9.79M | N/A |
Cash on Hand | $3.02M | N/A |
Debt to Equity | $1.68 | 57.33% |
Cash to Debt | 0.3081 | -72.22% |
Current Ratio | 0.7296 | -30.36% |